Lupin announced the appointment of Spiro Gavaris as President US Generics business. As part of Lupin’s senior leadership team, Gavaris will be responsible for the overall strategy, implementation and growth of Lupin’s US Generics business.

Gavaris joins Lupin with significant experience in the branded, generic and biotech industries. He most recently served as President of Speciality Generics business at Mallinckrodt Pharmaceuticals and the President of US injectables at Hikma.

Commenting on the appointment, Vinita Gupta, CEO, Lupin said, “Spiro brings strong pharma and biotech experience and has an established track record of success in building generics business across platforms, and in particular on the injectables front. We are delighted to welcome him to our leadership team.”